Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + CAPOX in Advanced Small Bowel/Ampulla Adenocarcinoma
NCT01208103Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2011
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in small intestine adenocarcinoma (SBA), ampulla of Vater adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started May 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
small intestine adenocarcinoma (SBA)ampulla of Vater adenocarcinoma
Beyond the preview
Go deeper on NCT01208103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208103.